Physician profile
Geetika Bhatt
NPI 1205193349
$1,127.79
in general payments reported to CMS, 2019-2025
17 companies · $718 in 2025
The $718 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $70.30 · 2024: $83.84 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $650 · Food and Beverage: $109 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $650.00 |
| Food and Beverage | $109.02 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Edwards Lifesciences Corporation | $83.84 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $69.03 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $59.17 | 2019-2025 | Enhertu |
| Genentech USA, INC. | $40.13 | 2019 | |
| Lilly USA, LLC | $28.17 | 2019 | |
| Genzyme Corporation | $25.18 | 2025 | |
| Emd Serono, INC. | $23.02 | 2019 | |
| Biogen, INC. | $21.27 | 2019 | |
| Clovis Oncology, INC. | $19.06 | 2019 | |
| Puma Biotechnology, INC. | $18.72 | 2020 | |
| Amgen INC. | $16.88 | 2019 | |
| Eisai INC. | $16.58 | 2019 | |
| Gilead Sciences, INC. | $15.92 | 2019 | |
| Foundation Medicine, INC. | $15.49 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $14.28 | 2019 | |
| Pfizer INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geetika Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.